
· updated
CagriSema in 2026: New EASD Data and the FDA Decision Ahead
CagriSema is Novo Nordisk’s once-weekly injection that combines two peptides: semaglutide (the GLP-1 medicine in Wegovy) and cagrilintide, a long-acting amylin analogue. It is not FDA-approved yet, but a decision is expected in Q4 2026, and on September 30, 2026, Novo presented new data at the EASD annual meeting showing reduced “food noise” and less fat around organs. Here is what the trials found, the side effects included, and where things stand as of October 2026.
Key facts
- What it is: a fixed combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, given as one injection once a week. Investigational, not approved, as of Oct 2026.
- FDA status: Novo filed for approval with the FDA on December 18, 2025. A decision is expected in Q4 2026.
- REDEFINE 1 (3,417 adults with obesity or overweight, 68 weeks, NEJM): average weight loss of 20.4% vs 3.0% on placebo, counting everyone who started.
- EASD, Sept 30, 2026: in a 52-week brain imaging study, Novo reported a 22.4% reduction in body weight versus placebo, plus less hunger, cravings and food preoccupation at weeks 22 and 52.
- Side effects: gastrointestinal effects in 79.6% of people on CagriSema vs 39.9% on placebo in REDEFINE 1, mostly nausea, constipation and vomiting.
What is CagriSema?
CagriSema pairs two hormone mimics that work in different ways. Semaglutide acts on the GLP-1 receptor, the same target as Wegovy and Ozempic. Cagrilintide mimics amylin, a hormone released alongside insulin that is involved in fullness after meals. Novo describes it as the first once-weekly combination of a GLP-1 and an amylin analogue to be filed for weight management.
Both components are peptides, which makes CagriSema a natural fit for this site. If you are new to the idea that weight-loss medicines are peptides, our explainer on why GLP-1s are peptides covers the basics.
What did the main trials show?
The two pivotal obesity trials, called REDEFINE, ran for 68 weeks:
- REDEFINE 1 (3,417 adults without type 2 diabetes): average weight loss was 20.4% on CagriSema vs 3.0% on placebo when counting everyone who started. Among people who stayed on treatment as planned, Novo reported 22.7% vs 2.3%. In that group, 60.2% lost at least 20% of their body weight, 40.4% lost at least 25%, and 23.1% lost at least 30%.
- Built to test the pairing: REDEFINE 1 also included groups on cagrilintide alone and semaglutide alone, so researchers could see what the combination adds over each part.
- REDEFINE 2 (1,206 adults with type 2 diabetes): among people who stayed on treatment, Novo reported 15.7% weight loss vs 3.1% on placebo. As with other GLP-1 medicines, people with diabetes tended to lose less weight.
What was new at EASD 2026?
At the European Association for the Study of Diabetes meeting on September 30, 2026, Novo presented analyses that look beyond the scale:
- Food noise: in a 52-week study using functional MRI, people on CagriSema reported less hunger, appetite, food preoccupation and cravings, and greater craving control, at weeks 22 and 52. Brain scans showed changed responses in regions linked to cravings, reward and behavioral control.
- Fat around organs: in an MRI sub-study of REIMAGINE 1 (189 adults with early type 2 diabetes, 40 weeks), CagriSema reduced fat in the abdomen and around the liver and pancreas versus placebo. Average weight loss in that trial was 14.3% at week 40.
- Bone: a post hoc analysis of REIMAGINE 2 (2,713 adults with type 2 diabetes, 68 weeks, 14.2% weight loss) offered what Novo called “preliminary reassurance” on bone changes.
The honest limits: these are company-presented analyses, some are post hoc, and the bone data are biomarkers rather than fracture or bone density outcomes. They add useful detail, but they are not new pivotal results.
Update, Oct 23, 2026: on October 20 Novo presented post hoc analyses showing about 25% average weight loss in women in REDEFINE 1, across menopause stages. See CagriSema in women.
Update, Nov 17, 2026: at ObesityWeek on November 14, Novo presented REDEFINE 9, a 309-person phase 3 trial of two lower doses (1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg). Average weight loss was about 21% at 68 weeks vs 2.0% on placebo (efficacy estimand). See lower-dose CagriSema results.
Side effects, told plainly
CagriSema’s side effects look like those of other GLP-1 medicines, at fairly high rates. In REDEFINE 1, gastrointestinal effects affected 79.6% of people on CagriSema vs 39.9% on placebo. Nausea was reported by 55% vs 12.6%, constipation by 30.7% vs 11.6%, and vomiting by 26.1% vs 4.1%. These effects were the main reason some people stopped: about 6% discontinued CagriSema for side effects vs 3.7% on placebo, per Novo’s June 2025 results.
How does it compare with other options?
Trials differ in length and population, so numbers across drugs are not a head-to-head comparison. For context, our retatrutide vs tirzepatide vs semaglutide page lays out the main obesity trials, and semaglutide vs tirzepatide covers the two approved weekly injections. The amylin approach is drawing more attention: also at EASD 2026, Lilly reported phase 2 data for its own amylin combination, which suggests more options in this class may follow.
When could CagriSema be available?
Novo submitted its application to the FDA and Health Canada in December 2025 and expects a decision in Q4 2026. Until the FDA acts, CagriSema is investigational: it can only be received inside a clinical trial, and there is no approved compounded version. Anything sold online as “CagriSema” today is not an approved product. For the status of peptides that are not FDA-approved, see our legal status tracker.
What it means for you
CagriSema is good news for people living with obesity: a new weekly option with strong trial results is close to an FDA decision, and new data suggest effects on appetite and organ fat beyond weight alone. It is not approved yet, its side effects are common, and pricing is unknown. Until then, the practical step is a conversation with a licensed provider about the approved options, which our GLP-1 price tracker helps compare.
Sources
- Novo Nordisk via BioSpace: CagriSema reduces food noise, organ and bone data at EASD 2026 (Sept 30, 2026)
- Patient Care: CagriSema alters food-cue responses, reduces organ fat in new analyses (Sept 30, 2026)
- Novo Nordisk: CagriSema filed for FDA approval (Dec 18, 2025)
- Novo Nordisk: REDEFINE 1 published in NEJM, 22.7% mean weight reduction (June 22, 2025)
- Applied Clinical Trials: REDEFINE 1 finds cagrilintide-semaglutide delivers over 20% weight loss (July 1, 2025)
- HCPLive: EASD 2026, EloraTZP vs tirzepatide (Sept 30, 2026)
Educational content only, not medical advice. Talk to a licensed provider about whether any medicine is right for you.